AIM:LID

Stock Analysis Report

Executive Summary

LiDCO Group Plc develops, manufactures, and sells hemodynamic monitoring equipment in the United Kingdom, the United States, Continental Europe, and internationally.

Snowflake

Fundamentals

Flawless balance sheet and overvalued.

Risks

  • LiDCO Group has significant price volatility in the past 3 months.
  • LiDCO Group is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has LiDCO Group's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-16.5%

AIM:LID

0.6%

GB Medical Equipment

-1.7%

GB Market


1 Year Return

-35.3%

AIM:LID

19.3%

GB Medical Equipment

-5.7%

GB Market

LID underperformed the Medical Equipment industry which returned 19.2% over the past year.

LID underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -5.8% over the past year.


Share holder returns

LIDIndustryMarket
7 Day-16.5%0.6%-1.7%
30 Day-22.4%10.0%-4.6%
90 Day-24.0%14.9%-3.2%
1 Year-35.3%-35.3%21.8%19.3%-1.3%-5.7%
3 Year-35.3%-35.3%53.7%45.6%17.8%4.0%
5 Year-74.9%-74.9%82.8%66.9%26.9%0.2%

Price Volatility Vs. Market

How volatile is LiDCO Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is LiDCO Group undervalued based on future cash flows and its price relative to the stock market?

1.42x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

LiDCO Group's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

LiDCO Group's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

LiDCO Group is loss making, we can't compare its value to the GB Medical Equipment industry average.

LiDCO Group is loss making, we can't compare the value of its earnings to the United Kingdom of Great Britain and Northern Ireland market.


Price Based on Expected Growth

Unable to calculate PEG ratio for LiDCO Group, we can't assess if its growth is good value.


Price Based on Value of Assets

LiDCO Group is good value based on assets compared to the GB Medical Equipment industry average.


Next Steps

Future Growth

How is LiDCO Group expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

80.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

LiDCO Group's revenue is expected to grow by 13.1% yearly, however this is not considered high growth (20% yearly).

LiDCO Group is not considered high growth as it is expected to be loss making for the next 1-3 years.

LiDCO Group's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.

Unable to compare LiDCO Group's earnings growth to the United Kingdom of Great Britain and Northern Ireland market average as it is expected to be loss making during the next 1-3 years.

Unable to compare LiDCO Group's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if LiDCO Group will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.


Next Steps

Past Performance

How has LiDCO Group performed over the past 5 years?

-72.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

LiDCO Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare LiDCO Group's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare LiDCO Group's 1-year growth to the GB Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if LiDCO Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if LiDCO Group has efficiently used its assets last year compared to the GB Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if LiDCO Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is LiDCO Group's financial position?


Financial Position Analysis

LiDCO Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

LiDCO Group has no long term commitments.


Debt to Equity History and Analysis

LiDCO Group has no debt.

LiDCO Group has not taken on any debt in the past 5 years.


Balance Sheet

High level of physical assets or inventory.

LiDCO Group has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

LiDCO Group has sufficient cash runway for 1.1 years based on current free cash flow.

LiDCO Group has sufficient cash runway for 1.1 years if free cash flow continues to grow at historical rates of 92.9% each year.


Next Steps

Dividend

What is LiDCO Group's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate LiDCO Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate LiDCO Group's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as LiDCO Group has not reported any payouts.

Unable to verify if LiDCO Group's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as LiDCO Group has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of LiDCO Group's dividends in 3 years as they are not expected to pay a notable one for United Kingdom of Great Britain and Northern Ireland.


Next Steps

Management

What is the CEO of LiDCO Group's salary, the management and board of directors tenure and is there insider trading?

4.0yrs

Average management tenure


CEO

Matt Sassone

4.0yrs

Tenure

UK£262,000

Compensation

Mr. Matthew Sassone, also known as Matt, has been the Chief Executive Officer of LiDCO Group plc since August 14, 2015. Mr. Sassone served as Senior Vice President of Global Marketing at ArjoHuntleigh AB.  ...


CEO Compensation Analysis

Matt's remuneration is about average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.

Matt's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.0yrs

Average Tenure

The tenure for the LiDCO Group management team is about average.


Board Age and Tenure

3.0yrs

Average Tenure

59.5yo

Average Age

The tenure for the LiDCO Group board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

BuyUK£9,00027 Mar 19
Peter Grant
EntityIndividual
Role
Chairman of the Board
Shares200,000
Max PriceUK£0.045
BuyUK£4,40027 Mar 19
Tim Hall
EntityIndividual
Role
CFO, Company Secretary & Director
Member of the Board of Directors
Shares100,000
Max PriceUK£0.044
BuyUK£4,40027 Mar 19
Philip Cooper
EntityIndividual
Role
Member of the Board of Directors
Shares100,000
Max PriceUK£0.044

Ownership Breakdown


Management Team

  • Terry O'Brien (64yo)

    Co-Founder & Member of Clinical Advisory Board

    • Tenure: 28.6yrs
  • David Band

    Co-Founder

    • Tenure: 28.6yrs
  • Tim Hall (56yo)

    CFO, Company Secretary & Director

    • Tenure: 0.4yrs
  • Matt Sassone

    CEO & Director

    • Tenure: 4.0yrs
    • Compensation: £262.00k
  • Shane Doorish

    Head of North America

    • Tenure: 2.6yrs

Board Members

  • Terry O'Brien (64yo)

    Co-Founder & Member of Clinical Advisory Board

  • Max Jonas

    Member of Clinical Advisory Board

  • Peter Grant (63yo)

    Non-Executive Chairman

    • Tenure: 2.3yrs
    • Compensation: £45.00k
  • Michael Pinsky

    Member of Clinical Advisory Board

    • Tenure: 13.8yrs
  • Tim Hall (56yo)

    CFO, Company Secretary & Director

    • Tenure: 0.4yrs
  • Matt Sassone

    CEO & Director

    • Tenure: 4.2yrs
    • Compensation: £262.00k
  • Phil Cooper (55yo)

    Non-Executive Director

    • Tenure: 3.0yrs
    • Compensation: £30.00k

Company Information

LiDCO Group Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: LiDCO Group Plc
  • Ticker: LID
  • Exchange: AIM
  • Founded: 1991
  • Industry: health care equipment
  • Sector: healthcare
  • Market Cap: UK£9.279m
  • Shares outstanding: 244.17m
  • Website: Click here

Number of Employees


Location

  • LiDCO Group Plc
  • 16 Orsman Road
  • London
  • Greater London
  • N1 5QJ
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LIDAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPJul 2001
LDGDB (Deutsche Boerse AG)YesOrdinary SharesDEEURJul 2001
LDRU.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDJul 2001

Biography

LiDCO Group Plc develops, manufactures, and sells hemodynamic monitoring equipment in the United Kingdom, the United States, Continental Europe, and internationally. The company provides a range of closed  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/17 20:41
End of Day Share Price2019/08/16 00:00
Earnings2019/01/31
Annual Earnings2019/01/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.